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Malaria, as one of the most lethal infectious diseases, has been causing much 
morbidity and mortality worldwide for decades. The causative parasites, Plasmodium spp., 
are extremely hard to eliminate because of their intricate life cycle and fast-emerging drug 
resistance. At present most malaria drug development programs have focused on the blood 
stages for curative treatment of malaria disease. The liver stage of malaria, an obligatory 
step of disease progression prior to blood stages, is an area of drug development that has 
been omitted for a long time because it is cumbersome to grow hepatocytes and parasites 
for drug screening assays. Liver stage drugs are important for the prophylaxis of all 
malarias as well as replacing toxic primaquine for dormant stages of P. vivax and P. ovale 
malaria. Because of the scarcity and urgent need of drugs specific for liver stage malaria, 
the purpose of this study is to identify novel, potent and non-toxic therapeutic agents from 
existing drugs and compounds. In collaboration with Gradient Biomodeling we used a 
virtual screen with a quantum physics model to identify potential novel target molecules. 
Data from a handful of liver stage in vitro screens including the Novartis dataset of 5,000 
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molecules was input to create a pharmacophore model and generate similarities utilizing 
additional quantum physics properties. We screened in silico by quantum modeling many 
millions of molecules to identify 45 unique potential compounds based on quantum scores. 
We obtained or synthesized nearly a dozen of those with half showing activity both in 
single oral dose in mice and in an in vitro liver stage P. berghei model. Prominent amongst 
the list was an isomer of cethromycin, which is a 3 quinoline with a ketolide. This was 
active with more than a log decrease in mice and acted synergistically with primaquine. 
Another simple concept used was identification of drugs with enterohepatic circulation that 
reach high hepatocyte concentrations relative to plasma like azithromycin, posaconazole, 
moxifloxacin and even cethromycin. The macrolide hybrids to quinoline may be a potent 
nontoxic set of molecules for liver stage malaria. 
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Malaria has been a lethal threat to people, especially children under 5 years old, in 
endemic areas of Africa, Asia and the Americas. According to the latest report, this 
parasitic disease has resulted in approximately 207 million cases and 627,000 deaths 
worldwide in 20121. High malaria morbidity and mortality have caused a catastrophic 
impact on the local economic and social development2,3. The amount of investments and 
control programs has dramatically increased since 2000. To be more specific, the number 
of households in sub-Saharan Africa owning at least one insecticide-treated bed net (ITN), 
an important part of vector control, has multiplied almost 20 times from 2000 to 20121. In 
addition to ITNs, indoors insecticide spraying plays a role in preventing mosquitoes from 
transmitting the disease to humans and rapid diagnostic testing is more readily available. In 
2005 there were only about 200,000 RDT’s distributed but in 2012 the number increased to 
more than 108 million. Likewise the number of artemisinin combination treatments has 
increased from 11 million in 2005 to 330 million in 2012. As a result, the mortality rate of 
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malaria has been reduced significantly by 42% in all ages and even higher among children 
under 5 years of age, which encouraged WHO to further set the goal towards 75% by 20151. 
As for prevention, despite all the efforts towards a long-desired effective vaccine, the best 
possible candidates we have until now are made of irradiated or attenuated whole 
sporozoites4–6. Therefore, chemotherapy remains a vital part of weaponry in the battle 
against malaria7.  
 
Liver stage 
One of the reasons that malaria is so hard to control and treat is its intricate life cycle 
between human and mosquito hosts. Moreover, the disease progression in the human 
consists of multiple stages and forms of the parasite. When an infected mosquito takes a 
blood meal, approximately one hundred sporozoites are injected and deposited under the 
host’s skin. Later these sporozoites can find their way to peripheral blood vessels in which 
they can eventually travel to liver sinusoids8. Sporozoites will traverse through several 
hepatocytes in search of a habitable one before they form an intracellular parasitophorous 
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vacuole in which growth and replication take place9. The number of days that parasites 
need to progress to the next stage by releasing thousands of merozoites produced in 
hepatocytes usually varies from species to species. The free-living merozoites then go on 
to invade erythrocytes, where the blood stage begins and leads to massive multiplication of 
even more parasites10. Malaria remains asymptomatic in patients until this burst production 
of parasites at the blood stage that results in serious symptoms and disease11. Due to this 
strong association between disease onset and parasite localization, most antimalarial 
measures including drug development have been focused on blood stages, leaving the 
importance of liver stage neglected by malaria community for a long time. In fact, if we 
want to practically cure and eventually eradicate malaria, killing liver stage parasites has 
several advantages compared to targeting blood stage parasites2,7. Because only a few 
sporozoites can actually reach and grow in hepatocytes after a mosquito bite, the liver stage 
is considered as a bottleneck of parasite development and we can stop the disease 
progression by eliminating parasites in the liver with effective pharmaceutical agents. 
Theoretically, a person receiving treatment for malaria who was bitten by another mosquito 
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a few days before treatment could still have liver stages not treated by artemisinin 
combination therapy. These liver parasites could be released after 6-10 days when drug 
levels are falling in the blood. Ideal drugs should be active against liver, blood and 
gametocyte stages. Tafenoquine shows promise for action against all stages but is still 
awaiting regulatory approval. 
 
Antimalarial drug development for liver stage 
Chemotherapy has been the most powerful strategy against malaria ever since 200 BC 
when Chinese herbalists first used Qinghaosu, also known as artemisinin, to treat patients. 
Another ancient drug, quinine, was first used in the 1600’s. Over the decades in 1900s, 
several new classes of antimalarial drugs had been discovered and widely used, including 
chloroquine, pyrimethamine, primaquine, atovaquone, the antibacterial apicoplast targeted 
drugs like azithromycin and so on. Among these drugs, primaquine (Table 3) is the only 
clinically approved one that has been shown capable of clearing both growing and dormant 
Plasmodium parasites in the liver12. Besides, most of the drug screening and discovery 
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projects have been concentrating on blood stages in the endeavor to treat the clinical 
symptoms13, leaving us with the scarcity of drugs against liver stage malaria. What makes 
this situation even worse is that administration of primaquine is always accompanied by 
some severe side effects like nausea and hemolysis (in patients with G6PD deficiency)14. 
Atovaquone is another approved drug for malaria prevention. While atovaquone can kill 
off actively growing parasites in the liver, it has no effect on the dormant hypnozoites of P. 
vivax and P. ovale15, which can lead to relapses of the disease long after clearance of 
parasites in the blood stream. It is evident that discovering new drugs against liver stage 
malaria is both necessary and urgent considering its critical role in the prevention of 
disease progression and relapse. 
 
Selection of novel liver stage drug candidates 
In order to overcome the scarcity of drugs against liver stage malaria, this study 
mainly focused on discovering new potential leads among existing drugs and compounds. 
Various strategies were applied to identify potential candidates from the literature and 
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databases based on their pharmacokinetic or quantum properties. Positive selections were 
further tested in both in vitro and in vivo assays to validate their inhibitory effect on parasite 
growth in hepatocytes. 
 
Enterohepatic circulation: Posaconazole and Bedaquiline 
About a liter of bile is made daily in the adult. Drug uptake into hepatocytes is by both 
carrier mediated transporters for polar drugs and by diffusion for lipophilic drugs. Cardiac 
glycosides, anion and cations have three separate active transporters. These actively 
secreted drugs are charged when entering the intestinal tract and are not resorbed. While 
molecular weight predominates in prediction of drugs with biliary route of elimination, 
other factors also influence the biliary route over the urinary route of drug elimination. In 
general, a molecular weight above 450 to 500 is favorable threshold for biliary excretion 
that progressively increases from about 15% for drugs below 450 MW to almost 100% for 
molecular weight above 600 to 700. In a study of similar cephalosporins16 addition of a 
hydroxide to a phenolic group halved biliary excretion for a cephalosporin of 575 MW.  
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Many other drugs that enter the bile into the upper intestine are passively absorbed via 
the intestines into the blood and passed through the hepatocytes into the bile again. This 
process is called enterohepatic circulation. Conjugation by the cytochrome P450 system 
generally enhances biliary elimination. Chloramphenicol is conjugated to the glucuronide, 
passes into the bile then the glucuronide is cleaved in the intestines by bacteria and the drug 
is resorbed to repeat the process. In this fashion drugs can undergo a lengthy enterohepatic 
circulation17–19.  
If a drug favors enterohepatic circulation, it should be considered as therapeutically 
advantageous for liver stage malaria because recycling within the system can dramatically 
prolong the availability of administered drug to parasite-infected hepatocytes as well as 
increasing effective concentration in the liver. With this notion in mind, a search among 
scientific literatures was conducted and identified two existing drugs with potential liver 
stage antimalarial activity. 
Posaconazole (Table 3) is mostly used as an antifungal agent to treat diseases induced 
by Candida20 and Aspergillus21 species. The drug is effective for both acute and chronic 
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Chagas disease22. In their recent study, a Brazilian research group showed posaconazole’s 
antimalarial activity with a relatively low IC50 of 2.6 µM for blood stages and ability to 
reduce P. berghei parasitemia by 71% when given to infected mice orally23. Furthermore, 
posaconazole was proved by other researchers to be extensively distributed in tissues and 
mainly excreted by feces after oral administration24–26. These properties of posaconazole 
implied its potential for liver stage antimalarial activity. 
Bedaquiline, the first new tuberculosis drug in more than forty years, was first 
discovered in 2005 by Koen Andries and his team27. According to this article, bedaquiline 
is a diarylquinoline compound with a substructure similar to quinoline and effective 
against multi-drug resistant M. tuberculosis species (Table 3). Bedaquiline selectively 
targets the Mycobacterium tuberculosis F1F0 ATP synthase, which in Plasmodium blood 
stages is present but not thought to be functional. More importantly, pharmacokinetic 
studies showed that orally administered bedaquiline was able to reach high concentration 
in tissues including liver and had an effective half life as long as 24 hours, which may 
overcome the lack of selectivity for the parasites. Additionally bedaquiline is a 1,2 
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substituted quinoline with a bromine in the 7 position. Taking these facts into consideration, 
bedaquiline would was a reasonable candidate drug for liver stage malaria testing. 
 
In silico quantum modeling: Cethromycin and other compounds 
Our collaborators in Gradient Biomodeling, LLC have developed and published an 
unconventional search technology for pharmaceutical agents, in which compounds are 
described rigorously based on their quantum properties rather than chemical structures. By 
inputting quantum descriptors of known antimalarial drugs as filters, the system can screen 
in silico through thousands of drugs and compounds to identify matches bearing similar 
quantum properties. Because these quantum attributes are usually associated with 
corresponding pharmacological activities, this method can serve as a powerful tool for 
discovering novel, potent and non-toxic antimalarial drugs that act in a similar manner as 
known drugs. Since this method has already been validated in screening compounds with 
blood stage antimalarial activity28, a new modeling system was established referring to 
chemicals that are effective for liver stage malaria for identifying prospective drugs. A 
 10 
battery of 5757 compounds was generated by combining Novartis ChEMBL-NTD 
dataset29 and validated liver stage antimalarial drugs from recent publications that 
investigated in vitro hepatocyte Plasmodium inhibition. These compounds were utilized to 
establish the modeling system that later screened over 65 million compounds from various 
databases in silico, identifying 45 potential candidates.  
The model matches the input molecules with identified candidates over numerous 
quantum scoring criteria. A representative image of matching the quantum components is 
shown in Figure 1 for A8 and GNF-Pf-1498 where the greater weight is given to the 
nonmacrolide quinoline on A8 and the nitrogen rich aromatic of GNF-Pf-1498 shown in 
red. A sample of matching quantum scores is shown in Table 1. Table 2 identifies the 
matched quantum score with the reference input molecules from the 5,000 compounds 
screened in the Meister data set. Cyclosporin A has a liver stage inhibition of 1.7 nM, 




Table 1. Matching quantum scores of input and output molecules for A1, A3 and A8. A1, 
A3 and A8 are matched with known anti-malarial agent cyclosporin A and monensin 
respectively based on similar quantum properties. 
 






A10 26 GNF-Pf-1498 
A5 22 
Monensin; Saquinavir; Sirolimus; Everolimus; 
GNF-Pf-1498 
A6 22 GNF-Pf-1498; Monensin 
A7 22 None 
A3 21 Cyclosporin A 
A14 20 None 
A4 20 None 
A12 20 Sirolimus; Everolimus 
A1 19 Cyclosporin A 
A15 19 Cyclosporin A; Everolimus 
A9 18 Everolimus 
A11 18 Everolimus 
A8 15 GNF-Pf-1498; Monensin 
Table 2. Summary of quantum scores with molecule identifications and reference 
molecules for scoring. Molecules predicted by quantum modeling system are sorted by 
quantum pattern scores. Compounds marked with green were available from chemical 
suppliers and tested in this study. Higher score implies greater possibility of bearing 
anti-malarial activity. 
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         GNF-Pf-1498                         A8 
Figure 1. Quantum similarity of GNF-Pf-1498 and the quinoline-macrolide hybrid A8 that 
is related to cethromycin.  
 
Cethromycin is chemically similar to one of the potential candidates A8, with only a minor 
difference in the orientation of the attached quinoline substructure and an extra carbon in 
the linker between the macrolide and 3-quinoline. Cethromycin was safe to use for 
community acquired pneumonia but was not superior to existing drugs and was denied 
approval by the FDA on basis of efficacy. In addition to its anti-bacterial activity, 
cethromycin reaches a higher concentration in tissues than plasma. Along with 
cethromycin, seven other candidate compounds that were available from chemical 





Materials and Methods 
Drugs and compounds 
Posaconazole was purchased from Schering-Plough (Kenilworth, NJ). Bedaquiline 
was purchased from Adooq Bioscience (Irvine, CA). Quinoline hydrochloride, 
Erythromycin ethyl succinate, D-mannitol hexabenzoate, 
(R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminomanganese(III) 
chloride and Hexa(o-tolyl)ditin were purchased from Sigma (St. Louis, MO). Amb356416, 
Amb3476561, Amb461470 and Amb1639503 were purchased from Ambinter (Orléans, 
France). Cethromycin was synthesized by and courtesy of Bryan T. Mott (NCATS, 
Bethesda, MD).  
 
P. berghei sporozoites 
P. berghei ANKA infected female Anopheles stephensi mosquitoes were dissected to 
obtain salivary glands. The glands were placed on ice in tubes containing Dulbecco's 
Modified Eagle's Medium (DMEM) and antibiotics. A homogenizer was used to gently 
 14 
grind the glands and release the sporozoites. The yield of sporozoites was counted on a 
hemacytometer. After extraction, sporozoites were diluted in culture media and used for 
infecting hepatoma cells and mice. 
 
In vitro assay 
HepG2 cell culture 
A circular coverslip was sterilized and placed in each well on a 24-well plate. HepG2, 
human hepatoma cells, were grown on these coverslips using Minimum Essential Medium 
(MEM) supplemented with 10% fetal bovine serum (FBS) and 1X Penicillin-Streptomycin 
(Pen-Strep) at 37°C and 5% CO2. 200,000 HepG2 cells were seeded in each well 24 hrs 
prior to infection. 
 
Hepa1-6 cell culture 
In each chamber of 8-well LabTek tissue culture slides, 50,000 mouse hepatoma cells, 
Hepa1-6, were seeded one day before infection. Cells were normally cultured in DMEM 
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supplemented with 10% FBS, 1X L-glutamine and 1X Pen-Strep at 37°C and 5% CO2. 
Once incubated with P. berghei sporozoites, the culture medium supplement was changed 
to 2.5% FBS, 1X L-glutamine and 2X Pen-Strep. 
 
Treatment preparation 
Different drugs and compounds were dissolved based on individual solubility and 
stored at -20°C. Stock concentrations ranged from 1 mM to 32 mM. Before compounds 




On a 96-well plate, 2500 cells in 250 µL culture medium were added in each well and 
incubated at 37°C and 5% CO2 for 3 days so that the cells could reach log phase. Several 
wells were filled with only medium to serve as blank controls. 3 days later, spent medium 
was removed and fresh medium containing different dilutions of drugs was added to 
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designated wells. Each dilution was tested in triplicates. Then the plate was covered and 
returned to incubator. After 2 days, 25 µL of alamarBlue (Invitrogen) indicator was added 
to each well and the plate was further incubated for 3 hours. The plate was read 
spectrofluorometrically (excitation, 550nm; emission, 590nm) and percentage of cell 
growth in each drug dilution was calculated with the following formula: ((FI 590 of test 
agent dilution- FI 590 of blank)/(FI 590 of untreated control- FI 590 of blank))*100. 
 
Infection of hepatocytes with Pb spz and Immunofluorescence assay 
After removing spent medium, 200 µL of fresh medium containing 60,000 
sporozoites extracted from infected mosquitoes were added to each chamber of hepatoma 
cell culture. Then the plate was spun down for 3 minutes at 300 x g and incubated at 37°C 
and 5% CO2 for 3 hours after which sporozoite containing medium was aspirated off from 
each chamber. Before treatment with drugs, the cells were washed four times with DMEM 
containing 10X Pen-Strep and 5 ug/mL fungicide. Different treatments were added to 
infected cells and the plate was returned to incubator. After 24 hours, fresh culture medium 
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containing drugs was added to each chamber. Approximately 42 hours post-infection, the 
growth medium was removed and 100% cold methanol was added for 15 minutes to fix the 
cells. After washing with sterile PBS, cells were incubated in PBS with 5% FBS for 
blocking. Then 2E6 anti-HSP70 antibody was diluted to 10 µg/mL in PBS with 5% FBS 
and added in a 200 µL volume to cells. One hour later, cells were washed with PBS and 
incubated with 10 µg/mL Alexafour 594 anti-mouse secondary antibody. In order to 
visualize hepatocytes, nuclear counterstain DAPI was incubated with cells for 5 minutes 
and then washed off. The plastic chambers and silicone gasket were removed and slide was 
fully dried before mounted and sealed with cover slides. When preparation was complete, 
slide was taken to the fluorescence microscope for examination. Representative areas were 
randomly selected from each chamber and the numbers of infected cells were counted for a 
similar number of microscopic fields. The level of inhibition was determined by comparing 




In vivo assay 
Treatment preparation 
Compounds that are soluble in water were dissolved in PBS, while those that are not 
soluble were prepared individually based on their solubility into oral suspensions. Final 
concentrations of compound dilutions ranged from 5 mg/mL to 10 mg/mL. All compound 
dilutions were freshly prepared and warmed at 37°C before being given to mice. 
 
Infection of mice with Pb sporozoites and drug delivery 
Six weeks old C57BL/6 mice with weight of 20-22 g were divided into groups of 
three. Before infection, mice were warmed with a heat lamp to dilate their tail veins for 
injection. A restrainer was used to hold each mouse in position and 12,000 Pb sporozoites 
in a 200 µL volume were injected into mice through tail veins with syringes. Two hours 
after injection, different dilutions of drugs in 100-200 µL volumes were delivered to mice 
by gavage using a plastic feeding tube. A second dose of drugs was given 24 hours after the 
first one to the mice that were on a daily dosing regimen.  
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Liver harvest of infected mice 
Approximately 6 and 40 hours post-infection, mice infected with Pb sporozoites were 
anesthetized by inhaling Metofane® and sacrificed for harvesting whole livers. Each mouse 
liver was immediately put into 10 mL of Trizol® Reagent and fully homogenized. Then the 
homogenate was divided into small aliquots of 1 mL in Eppendorf tubes and stored at 
-80°C. 
 
Whole tissue RNA isolation 
Mouse liver homogenate in Eppendorf tubes was thawed on ice and resuspended by 
vortexing. Then 200 µL of chloroform (1/5 of initial volume) was added to each tube and 
mixed by inverting the tubes. After incubating for 3 minutes at room temperature, tubes 
were centrifuged at 12,000 x g and 4°C for 15 minutes. Centrifugation separates the 
mixture into three phases and RNA is exclusively contained in the top aqueous phase, 
which is usually yellowish due to high content of blood and iron in the liver homogenate. 
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The RNA containing aqueous phase was transferred to a new tube carefully without 
drawing any of the interphase that contains DNA. 500 µL of 100% isopropanol was added 
and tubes were inverted several times to precipitate RNA before further incubation for 10 
minutes at room temperature. Eppendorf tubes were then centrifuged at 12,000 x g and 4°C 
for 10 minutes after which supernatant was removed without touching the RNA pellets. To 
wash RNA, 1 mL of 75% ethanol was added to resuspend pellets and tubes were 
centrifuged again at 7500 x g and 4°C for 5 minutes. Then 50-70 µL of ultra pure water 
heated to 55°C was added to each tube to dissolve RNA pellet when ethanol was 
completely removed. RNA dissolved in water was either kept on ice for upcoming 
experiment or stored at -80°C. 
 
Real-time quantitative PCR 
Isolated whole liver RNA was first used to generate cDNA by reverse-transcription 
PCR. The initial concentration of each RNA sample was measured on a NanoDrop 
microvolume spectrophotometer after which all samples were diluted to approximately 
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100 ng/mL for reverse-transcription reactions. For a 30 µL reaction, the components were 
set up as: 3.5 µL of nuclease-free water, 3 µL of 10X Buffer II and 10 mM dNTPs, 6 µL of 
MgCl2 solution, 1.5 µL of 50 µM Random Hexamers, RNase Inhibitor and MuLV Reverse 
Transcriptase, 10 µL of RNA sample. cDNA products were stored at -20°C. 
For a 10 µL real-time quantitative PCR, the components were set up as: 0.2 µL of 10 
µM forward and reverse primer 18s P. berghei, 5 µL of 2X SYBR Green PCR Master Mix, 
1.6 µL of nuclease-free water, and 3 µL of cDNA sample. The annealing temperature of the 
reaction was determined based on the predicted melting temperatures of the primers. To 
quantify the relative amounts of parasite specific protein and the murine Hypoxanthine 
Guanine Phosphoriboayltransferase (HPRT) housekeeping protein, a standard line was 
created using either plasmids with the coding gene or mixtures of randomly selected 
samples of designated concentrations. All test subjects were done in duplicates including 
positive and negative controls. When real-time PCR was finished, all data were baselined 
and normalized to the housekeeping gene before further analysis. The specific sequences 
of primers (The Core DNA Analysis Facility – JHU, Baltimore, MD) were: 5’- 
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GGAGATTGGTTTTGACGTTTATGCG-3’ and 5’- 
AAGCATTAAATAAAGCGAATACATCCTTA-3’ for Pb ANKA 18s and 5’- 
TCCCAGCGTCGTGATTAGC-3’ and 5’- CGGCATAATGATTAGGTATACAAAACA-3’ 














Nomenclature, abbreviation and chemical structure 
For unknown compounds, simplified names were assigned to each one for 
convenience. All drugs are also referred by their abbreviations in tables and graphs. In 
Table 3, all drugs and compounds are listed along with their individual molecular weights 
and chemical structures. 
 
Table 3. List of drugs and compounds. Abbreviations and chemical structures of all tested 
drugs and compounds are shown in this table. Additional information related to chemical 
properties is listed. Compounds with molecular weights above 450 to 500 are favorable for 
enterohepatic circulation. XLogP3-AA is used to predict the lipophilicity of chemical, 





  Chemical structure 
Primaquine 
MW 259.3 
XLogP3-AA                  2.2 
H-Bond Donor                2 
H-Bond Acceptor            4 






XLogP3-AA                  4.6 
H-Bond Donor                1 
H-Bond Acceptor           11 





XLogP3-AA                  7.2 
H-Bond Donor                1 
H-Bond Acceptor            4 





XLogP3-AA                    2 
H-Bond Donor                0 
H-Bond Acceptor            1 





XLogP3-AA                  2.7 
H-Bond Donor                5 
H-Bond Acceptor           14 






XLogP3-AA                  10 
H-Bond Donor                6 
H-Bond Acceptor            9 






XLogP3-AA                  5.3 
H-Bond Donor                  2 
H-Bond Acceptor              14 





XLogP3-AA                  5.4 
H-Bond Donor                2 
H-Bond Acceptor           12 
Polar Surface Area            163 






XLogP3-AA                  5.4 
H-Bond Donor                2 
H-Bond Acceptor           12 
Polar Surface Area            163 






XLogP3-AA                  9.8 
H-Bond Donor                0 
H-Bond Acceptor           12 































In vitro assay 
Infection of hepatocytes with Pb spz and Immunofluorescence assay 
All prepared slides were left overnight at 4°C after mounting and later examined 
under a fluorescence microscope. Because there were a great number of infected cells in 
most chambers, it was not practical to count the complete slide area manually. Therefore, 
2-8 representative areas, varied in different experiments, were randomly selected for 
counting and calculating percentage of inhibition. The number of infected hepatoma cells 
treated with different drug and compound dilutions and percentages of inhibition are 
summarized in Table 4. In general, primaquine, posaconazole and bedaquiline show 
dose-dependent inhibitory effect on in vitro liver stage parasite infection. Among all drugs 
and compounds tested, primaquine at 20 µM and A3 at 10 µM are able to reduce parasite 
multiplication by over 90 percent, while bedaquiline at 40 µM, cethromycin at 20 µM and 
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A2 at 10 µM display relatively lower, but still promising inhibitory effect. Cethromycin at 
40 µM and S3 at 10 µM were not countable because most hepatoma cells in these two 
chambers were killed by drugs’ toxic effect. 
In Figure 2a, large amount of untreated cells are infected and evenly distributed across 
the entire representative area, showing high rate of infection. In sharp contrast, only one 
cell in Figure 2b (PQ, 20 µM) and Figure 2c (A3, 10 µM) is infected. By comparing Figure 
2d (BDQ 20 µM) and 2e (BDQ 40 µM), it is evident that there are fewer cells infected 
when treated with higher concentration of bedaquiline, suggesting a dose-dependent effect. 
Figure 2f (CEY, 40 µM) shows a representative area in which cell density is much lower 















PQ 10 13.17±0.73 61.9 
PQ 20 3.13±0.46 90.9 
PSZ 10 26.45±1.15 23.6 
PSZ 20 21.5±0.9 37.9 
Exp 2 
QN 20 122±10 11.6 
ERY 20 106±8 23.2 
QN 20+ ERY 20 97±4 29.7 
Exp 3 
BDQ 20 34.0±4.0 41.9 
BDQ 40 16.0±1.0 72.7 
CEY 20 28.0±3.0 52.1 
CEY 40 N/A N/A 
A9 10 45.5±3.5 7.1 
A11 10 48.5±2.5 1.0 
A7 10 N/A N/A 
A1 10 35.0±2.0 28.6 
A2 10 47.0±4.0 4.1 
A3 10 1.5±0.5 96.9 
A4 10 22.5±0.5 54.1 
Table 4. Percent inhibition of infected hepatocytes treated with different drugs and 
compounds. Immunostained slides were examined under fluorescence microscope. The 
infection rate of hepatoma cells varied from experiment to experiment. Number of infected 
cells was averaged among randomly selected areas in each chamber and percentage of 
inhibition was determined relative to untreated cells. 
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 c d 
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Figure 2. Immunofluorescence images of Pb infected hepatocytes treated with drugs and 
compounds. (a) Negative control: high infection rate of untreated cells; (b) PQ 20 µM and 
(c) A3 10 µM: parasite proliferation remarkably reduced; (d) BDQ 20 µM and (e) BDQ 40 
µM: higher concentration of BDQ demonstrated greater inhibitory effect; (f) CEY 40 µM: 
decreased cell density induced by cytotoxicity. Blue: nucleus of hepatoma cells; Red: Pb 
liver stage parasites. 
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Cytotoxicity assay 
Each drug or compound was tested in 5 different concentrations ranging from 5 µM to 
80 µM and each concentration was done in triplicates. Fluorescence readouts were 
gathered and processed. The toxicity level of each drug or compound dilution was 
described as percentage growth of untreated cells. Figure 3 summarizes the cytotoxicity 
effects of all compounds and concentrations on hepatoma cells. Among approved drugs, 
both posaconazole and bedaquiline are well tolerated by cells in all tested concentrations 
but cethromycin and primaquine start to display toxicity when the concentration increases. 
However, the toxicity of cethromycin should be considered much less problematic than 
primaquine because at concentration of 40 µM more than 50 percent of cells can still 
survive in cethromycin while almost all cells are dead with 40 µM primaquine. In terms of 
the other compounds, there is a conspicuous and universal trend in which cytotoxicity 
increases substantially with concentration. As the most toxic test molecule of all, S3 
remains lethal to hepatoma cells even at the lowest concentration of 5 µM. 
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Figure 3. Cytotoxicity of drugs and compounds at different concentration, as measured by 
alamarBlue® indicator. Cells were seeded and incubated for 3 days to reach log phase and 
then treated with drugs and compounds for 2 days. Number of viable cells is positively 
correlated with strength of fluorescence. Background signal was deducted by measuring 
fluorescence of medium alone. Approved drugs including PSZ, BDQ and CEY showed 
mild to none toxicity to cells, while the other compounds gradually displayed toxicity with 
increasing concentration. 
 
In vivo assay 
According to a previous study, dosing mice infected by P. berghei with primaquine at 
30 mg/kg can clear liver stage parasite. In this study, two different doses of primaquine 






























control) and 15 mg/kg to kill most of parasites while leaving a small portion for evaluating 
drug synergy. 
 
Posaconazole and bedaquiline 
Both drugs were tested in two different doses of 50 and 100 mg/kg in mouse model. 
Furthermore, bedaquiline at 100 mg/kg was combined with primaquine at 15 mg/kg to 
explore the possibility of synergistic effect between these two drugs. Due to bedaquiline’s 
long half life, mice were given only one dose of the drug while the other drugs were 
administered twice, 24 hours apart from each other, before mice were sacrificed. As Figure 
4 shows, both posaconazole and bedaquiline can inhibit parasite growth in mouse liver and 
their antimalarial activity is dose-dependent. Between these two drugs, bedaquiline is more 
potent, demonstrated by up to 70 percent reduction at 100 mg/kg. An even more important 
conclusion is that bedaquiline, when combined with a lower dose of primaquine, can 
reduce parasite load in liver to the same level as primaquine at 50 mg/kg, which is 
considered as elimination of parasites in this study. 
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Figure 4. Real-time PCR quantification of parasite load in mice treated with BDQ and PSZ. 
BDQ was administered only once while the other drugs were given twice 24 hours apart 
from each dose. Both PSZ and BDQ demonstrated dose-dependent inhibitory effect while 
BDQ possessed higher potency. BDQ combined with low dose of PQ was able to clear 
actively growing parasites in mice liver. 
 
Cethromycin and other compounds 
In addition to cethromycin, erythromycin and quinoline were included in this 
experiment (Figure 5). Cethromycin and erythromycin share a remarkable similarity 
because the ketolide structure of cethromycin is derived from erythromycin by substituting 






























ring30. Quinoline itself and combination with erythromycin were also tested to investigate 
if quinoline plays a role in the antimalarial activity of cethromycin. As in the previous 
experiment, cethromycin was tested in different doses and administered along with a lower 
dose of primaquine to explore synergistic drug effect. Of the seven compounds tested in 
vitro, only A1, A3 and A4 demonstrated measurable inhibitory effect on parasite infection 
of hepatoma cells. Therefore, these three compounds were further validated in mouse 
model at dose of 50 mg/kg. Due to limited availability of cethromycin, only one dose was 
given to mice while other drugs and compounds were administered twice.  
Consistent with results from in vitro assay, quinoline, erythromycin and their 
combination measured only marginal inhibitory effect on parasite growth. Although 
cethromycin at 12 mg/kg only demonstrate minor effectiveness, a gradual dose response 
was observed after increasing the dose to 50 mg/kg, at which cethromycin was able to 
reduce parasite load by 60 percent. Again we were able to achieve parasite elimination by 
combining cethromycin at a relatively low dose of 12 mg/kg with primaquine at 15 mg/kg. 
While cethromycin at 12 mg/kg showed minimal inhibition at about 16%, combination 
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with low dose primaquine at 15 mg/kg (83% inhibition) showed higher 99% inhibition. 
Based on these results, it is safe to say that cethromycin is the most potent one of the tested 
drugs in this study. Although A3 compound did not demonstrate the same level of 
effectiveness as in vitro assay, all three drugs obtained from Ambinter (A1, A3 and A4) 
reduced parasite load by more than 50 percent without causing any serious or conspicuous 






Figure 5. Real-time PCR quantification of parasite load in mice treated with CEY and 
other compounds. CEY was administered only once while the other drugs were given twice 
24 hours apart from each dose. Two drugs related to CEY, QN and ERY, had only marginal 
effect on parasite growth. CEY’s effectiveness increased with dosage, reaching 60% 
reduction at 50 mg/kg. CEY was also able to eliminate parasite infection when combined 
with low dose of PQ. All three compounds from Ambinter demonstrated significant 































Inhibition of parasite growth (%) 
Mean SEM 
PQ 50 99.9 0.0 
PQ 15 82.2 3.8 
Cat 1 
PSZ 50 19.5 9.4 
PSZ 100 41.2 7.5 
BDQ 50 42.9 4.8 
BDQ 100 70.7 4.6 
PQ 15+BDQ 100 99.7 0.2 
Cat 2 
QN 25 3.4 1.9 
ERY 25 1.5 1.5 
QN 25+ERY 25 6.5 1.8 
CEY 12 15.8 2.1 
CEY 25 41.1 10.0 
CEY 50 58.2 8.8 
PQ 15+CEY 12 99.7 0.1 
Cat 3 
A1 50 58.8 9.0 
A3 50 56.2 8.9 
A4 50 68.0 13.4 
Table 5. Percent reduction of parasite load in livers of mice infected with P. berghei 
sporozoites. Mice were infected with P. berghei by intravenous injection of 12,000 
sporozoites. All drugs and compounds except for CEY and BDQ were given twice every 
24 hours. Parasite load in liver was determined by quantification of parasite specific 18s 
RNA with real-time PCR. Percentages of inhibition were calculated relative to respective 





In order to eventually eradicate malaria, transmission prevention and curative 
treatment are two requirements that must be satisfied. However, this goal can not be 
achieved by targeting the blood stage for 4 reasons: 1) Plasmodium parasites undergo 
extensive multiplication in erythrocytes and spread out with blood flow, which makes them 
hard to clear from the body; 2) Massive replication dramatically increases the possibility of 
emergence of drug-resistant strains; 3) Unless the drug works on gametocytes as well, 
parasites can still be transmitted to mosquitoes when taking blood meals from infected 
humans; 4) P. vivax and P. ovale can form hypnozoites in hepatocytes and lead to relapses 
when they are reactivated at a much later date. In contrast, the liver stage provides us with 
a great opportunity to overcome these obstacles. Because there are many fewer 
multiplications in invaded hepatocytes, it is easier to achieve complete clearance of 
parasites including hypnozoites and the chance of drug resistance emergence is greatly 
limited. Once parasites are constrained and killed at the liver stage, disease no longer has 
the chance to progress to the blood stage, hence blocking any further infection or 
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transmission. Taking all advantages into consideration, the importance of the liver stage 
has surely been underestimated. Besides, the best option we have now for treating liver 
stage malaria is primaquine, which is not safe enough to be used widely. Under these 
circumstances, discovering novel and potent drugs for liver stage malaria becomes 
necessary and urgent and developing new drugs from the ground up in the conventional 
way is no longer applicable. 
The ultimate purpose of this study is to discover liver stage antimalarial activity in 
existing drugs. Identification of potential candidate drugs was accomplished by searching 
for drugs that favor enterohepatic circulation or share quantum properties with known 
antimalarial drugs. To validate the effectiveness of each drug or compound, they were 
tested in both in vitro and in vivo assays. The in vitro assay, which is medium-throughput 
and manageable, was a modification of methods described before31. As for the in vivo test, 
we introduced a complete methodology that can quantify parasite load in whole liver in Pb 
infected mice with real-time fluorescence PCR. This test is advantageous because it not 
only mimics the actual infection and drug dynamics but also demonstrates effectiveness of 
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drugs more precisely. 
Of the two drugs found to be extensively distributed in liver, posaconazole was 
previously proved to have blood stage antimalarial activity while bedaquiline carries a 
substructure similar to quinoline. Both drugs displayed dose-dependent effectiveness and 
are non-toxic to hepatoma cells. Although bedaquiline alone was not able to inhibit 
parasite growth completely, combination with low dose of primaquine reached same level 
of inhibition as primaquine at 50 mg/kg. This drug combination can be considered as a 
promising alternative to primaquine alone, a curative treatment with less toxic effect of 
primaquine. 
Cethromycin and the other three Ambinter compounds demonstrated liver stage 
antimalarial activity as well. Cethromycin is closely related to compound A8 that shares 
quantum properties with GNF-Pf-1498 (Figure 1). Despite its minor cytotoxicity, 
cethromycin at a low dose of 25 mg/kg can reduce parasite load in mouse liver by 
approximately same percentage as bedaquiline at a dose two times higher, indicating 
cethromycin has a relatively higher potency. The dose of 25 mg/kg in the mouse is close to 
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the 150 mg single daily oral dose in adults, which is 3 mg/kg in humans. Mouse dosing 
conversion from humans multiplies by 11 or 12. The higher tolerated dose in humans is 300 
mg/kg, which would be related to the 50 mg/kg dose in mice. Furthermore, cethromycin, 
when combined with low dose of primaquine, can also achieve parasite clearance in 
hepatocytes at a much lower dose than bedaquiline. The fact that the level of inhibition of 
cethromycin and primaquine combination was higher than the sum of their individual 
percentages implied a possible synergistic drug effect between these two drugs. The liver 
stage assay used here injects supraphysiologic doses of 10,000 sporozoites, which is 
almost 100 times the infectious dose of one hundred sporozoites that mosquitoes deliver. 
Cethromycin may be more effective at the more physiologic sporozoite inoculums. Further 
studies are warranted on cethromycin to measure blood and gametocyte stage inhibition 
concentrations. A1, A3 and A4 demonstrated effectiveness in both tests, further validating 
the feasibility of quantum modeling search technology. However, these three compounds 
are all toxic to hepatoma cells starting at 40 µM. To tackle this problem, the quantum 
components of these three compounds that are responsible for the antimalarial activity will 
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be located for molecular optimization or de novo drug design, during which cytotoxicity is 
reduced or removed while antimalarial activity is maintained. 
Herein is reported a methodology of drug discovery and identification of three 
existing drugs and three compounds with liver stage antimalarial activity. Although further 
improvements are needed to generate more accurate results and increase throughput 
capacity, this is a practical attempt to discover novel, potent and non-toxic drugs against 
liver stage malaria. With incremental interest in liver stage drug development, we should 
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